Correction to: Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors (Breast Cancer, (2022), 29, 1, (77-91), 10.1007/s12282-021-01282-5)

Yuna Suzuki, Wu Wenwen, Tomohiko Ohta, Shin ichi Hayashi

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original publication of the article, the funding information should be revised as below. Funding This study was supported by AstraZeneca K.K., Ministry of Education, Culture, Sports, Science and Technology of Japan, and Smoking Research Foundation.

Original languageEnglish
Pages (from-to)185
Number of pages1
JournalBreast Cancer
Volume29
Issue number1
DOIs
Publication statusPublished - 2022 Jan
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Correction to: Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors (Breast Cancer, (2022), 29, 1, (77-91), 10.1007/s12282-021-01282-5)'. Together they form a unique fingerprint.

Cite this